Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support

Journal of Clinical Oncology

Volumn 24, Issue 22, 2006, Pages 3611-3618

  Quintela Fandino, Miguel ^a   López, Joaquín Martínez ^a   Hitt, Ricardo ^a   Gamarra, Soledad ^a   Jimeno, Antonio ^a   Ayala, Rosa ^a   Hornedo, Javier ^a   Guzman, Cecilia ^a   Gilsanz, Florinda ^a   Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN 19; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; PEPTIDES AND PROTEINS; PROGESTERONE RECEPTOR; PROTEIN EGP2; PROTEIN P1B; PROTEIN PS2; TAMOXIFEN; THIOTEPA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CALCIUM BINDING PROTEIN; EGP 2 ANTIGEN, HUMAN; EGP-2 ANTIGEN, HUMAN; KERATIN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PHOSPHOLAMBAN; PRESENILIN 2; PSEN2 PROTEIN, HUMAN; RNA; RNA PRECURSOR; STAMP V REGIMEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; APHERESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SIZE; CANCER SURVIVAL; CORRELATION ANALYSIS; DNA PROBE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MICROMETASTASIS; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA ISOLATION; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; CHEMISTRY; GENETICS; MIDDLE AGED; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KERATINS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PACLITAXEL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PRESENILIN-2; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA PRECURSORS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; THIOTEPA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33747079859     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0576     Document Type: Article

References (40)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
3. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998
4. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
5. Lacroix H, Iglehart JD, Skinner MA, et al: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4:145-151, 1989
6. Niehans GA, Singleton TP, Dykoski D, et al: Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230-1235, 1993
7. Braun S, Schlimok G, Heumos I, et al: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890-1895, 2001
8. Pantel K, Schlimok G, Braun S, et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424, 1993
9. Vredenburgh JJ, Peters WP, Rosner G, et al: Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: The role of induction chemotherapy. Bone Marrow Transplant 16:815-821, 1995
10. Diel IJ, Kaufmann M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652-1658, 1996
11. Vannucchi AM, Bosi A, Glinz S, et al: Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haematol 103:610-617, 1998
12. Cooper BW, Moss TJ, Ross AA, et al: Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 16:3509-3517, 1998
13. Braun S, Hepp F, Sommer HL, et al: Tumor-antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. Int J Cancer 84:1-5, 1999
14. Mansi JL, Gogas H, Bliss JM, et al: Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study. Lancet 354:197-202, 1999
15. Braun S, Pantel K, Muller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533, 2000
16. Lyda MH, Tetef M, Carter NH, et al: Keratin immunohistochemistry detects clinically significant metastases in bone marrow biopsy specimens in women with lobular breast carcinoma. Am J Surg Pathol 24:593-1599, 2000
17. Gerber B, Krause A, Muller H, et al: Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19:960-971, 2001
18. Gebauer G, Fehm T, Merkle E, et al: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: Clinical outcome during long-term follow-up. J Clin Oncol 19:3669-3674, 2001
19. Schneeweiss A, Diel I, Hensel M, et al: Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy. Ann Oncol 15:1627-1632, 2004
20. Kasimir-Bauer S, Oberhoff C, Schindler AE, et al: A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: Methods, prognostic significance and implication for alternative treatment protocols. Int J Oncol 20:1027-1034, 2002
21. Witzig TE, Bossy B, Kimlinger T, et al: Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin Cancer Res 8:1085-1091, 2002
22. Wong IH, Yeo W, Chan AT, et al: Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: Potential prognostic implications. Int J Oncol 18:633-638, 2001
23. Hu XC, Chow LW: Detection of circulating breast cancer cells with multiple-marker RT-PCR assay. Anticancer Res 21:421-424, 2001
24. Xenidis N, Vlachonikolis I, Mavroudis D, et al: Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:849-855, 2003
25. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 20:3404-3412, 2002
26. Silva JM, Dominguez G, Silva J, et al: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 7:2821-2825, 2001
27. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
28. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
29. Barz H, Barz D: The prevalence of single and synchronous multiple tumours in autopsy series and its dependence on age. Arch Geschwulstforsch 47:428-436, 1977
30. Braun S, Kentenich C, Janni W, et al: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80-86, 2000
31. Thomas PA, Kirschmann DA, Cerhan JR, et al: Association between keratin and vimentin expression, malignant phenotype, and survival in post-menopausal breast cancer patients. Clin Cancer Res 5:2698-2703, 1999
32. Fuchs IB, Lichtenegger W, Buehler H, et al: The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 22:3415-3419, 2002
33. Zajchowski DA, Bartholdi MF, Gong Y, et al: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61:5168-5178, 2001
34. Woelfle U, Cloos J, Sauter G, et al: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679-5684, 2003
35. Woelfle U, Sauter G, Santjer S, et al: Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 10:2670-2674, 2004
36. Bosma AJ, Weigelt B, Lambrechts AC, et al: Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8:1871-1877, 2002
37. Helfrich W, ten Poele R, Meersma GJ, et al: A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. Br J Cancer 76:29-35, 1997
38. Pallisgaard N, Hokland P, Bi W, et al: Selection of referente genes for the European standardization and quality control program of real-time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual disease follow up in leukemia patients. Blood 98:4467-4475, 2001
39. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:2002-2007, 2001
40. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005